Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus
- Development stage
- Phase 4
- Lead developer
- Junlebao Dairy
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus is a species of probiotic bacteria commonly used as a dietary supplement. It is known for its ability to modulate the gut microbiota and immune system. Studies have investigated its potential therapeutic effects across various conditions, including improving oral flora, managing metformin-induced diarrhea, preventing bacterial and viral infections in infants, and influencing immune responses in conditions like systemic lupus erythematosus and atopic dermatitis. It has also been studied for its role in polycystic ovary syndrome, obesity, psoriasis, Helicobacter pylori eradication, constipation, and periodontitis.
- Brand names
- Lcr Restituo
- Other names
- Lactobacillus casei rhamnosusLacticaseibacillus rhamnosusL. rhamnosusLactobacillus casei subsp. rhamnosus
02
Targets
FOXP3 (Forkhead box protein P3)IL10 (Interleukin-10)IL-2 (Interleukin 2)IL-6 (Interleukin 6)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on lactobacillus rhamnosus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus.